Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) this summer.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of thyroid malignancies, including Dr. Steven Sherman from the MD Anderson Cancer Center in Houston, Texas, Drs. Douglas Ball and Barry Nelkin from Johns Hopkins University in Baltimore, Maryland, and Dr. Martin Schlumberger from the Institut Gustave Roussy in Paris, France. This will be a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic MTC. Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of progression-free survival. In a planned event-driven analysis, the study size provides 90% power to detect a 75% increase in progression-free survival in patients with documented progressive disease prior to study entry. Secondary endpoints will include overall survival, objective tumor response rate, and changes in serum biomarkers (carcinoembryonic antigen and calcitonin). Additional secondary endpoints will b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... today that they have been acquired by Roche (SIX: ... a privately held company that provides a big data ... sequencing (NGS) data for the academic and translational research ... Unit, and will continue to focus on development of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... it has entered into a Cooperative Research ... Army Medical Research Institute of,Infectious Diseases (USAMRIID). ... use of the Company,s patented pressure cycling ...
... and safety of food supply, as well as increasing concerns ... to experience spiraling growth given the recent success of commercialized ... pipeline. , ... San Jose, California ...
... Update on Key Regulatory Milestones, SEATTLE, Sept. 11 ... MTA: CTIC) announced today that it will host an,investor ... investor day will,provide an update from executive management on ... meeting will be an,invitation-only event. A webcast and live ...
Cached Biology Technology:Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 2Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 3Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 4Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 5Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... honeybee hives arrests the growth of prostate cancer cells and ... at the University of Chicago Medicine. Caffeic acid phenethyl ... propolis, the resin used by bees to patch up holes ... natural remedy for conditions ranging from sore throats and allergies ...
... Biology Reports published today argues that recent advances ... of the global demand for liquid transportation fuels, drastically reducing ... burning fossil fuels, without having an impact on food production. ... of detrimental climate change is the emission of greenhouse gasses ...
... brain activity in the rat brain that play a ... decision-making. The discovery, which builds on the team,s previous ... post-traumatic stress syndrome. The researchers previously identified patterns ... region critical for memory storage. The patterns sometimes represented ...
Cached Biology News:Beehive extract shows potential as prostate cancer treatment 2Beehive extract shows potential as prostate cancer treatment 3Better plants for biofuels 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
Biology Products: